Passive perinatal immunotherapy via transamniotic antibody delivery

Area of Science:

• Perinatal medicine
• Immunology
• Developmental biology

Background:

• Therapeutic antibody delivery to the fetus is challenging.
• The amniotic cavity is a potential route for fetal administration.
• Investigating novel methods for fetal/neonatal therapeutic delivery is crucial.

Purpose of the Study:

• To determine if the amniotic cavity/fluid is a viable route for administering therapeutic antibodies to the fetus/neonate.
• To assess the feasibility of transamniotic fetal immunotherapy (TRAFIT).

Main Methods:

• Pregnant rodents received intra-amniotic injections of human IgG at varying concentrations or saline.
• Human IgG levels were quantified in neonate and maternal serum, bone marrow, spleen, thymus, and brain via ELISA.
• Statistical analysis used median regression with Bonferroni correction.

Main Results:

• Overall fetal survival was 83% with no significant difference between groups.
• Human IgG was detected in all tested fetal tissues and serum across all injected concentrations.
• A dose-dependent relationship was observed between IgG concentration and fetal IgG load in specific tissues.

Conclusions:

• Intra-amniotic administration of IgG antibodies successfully achieved high levels in fetal/neonatal circulation in a rodent model.
• Transamniotic fetal immunotherapy (TRAFIT) presents a practical strategy for managing certain perinatal diseases.
• This method offers a potential new avenue for fetal and neonatal therapeutic interventions.